These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 16322294)

  • 21. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
    Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer.
    Bollschweiler E; Besch S; Drebber U; Schröder W; Mönig SP; Vallböhmer D; Baldus SE; Metzger R; Hölscher AH
    Ann Surg Oncol; 2010 Dec; 17(12):3187-94. PubMed ID: 20585867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
    Langer R; Specht K; Becker K; Ewald P; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Verh Dtsch Ges Pathol; 2004; 88():207-13. PubMed ID: 16892554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.
    Hölscher AH; Drebber U; Schmidt H; Bollschweiler E
    Ann Surg; 2014 Nov; 260(5):779-84; discussion 784-5. PubMed ID: 25379849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
    Miyata H; Yoshioka A; Yamasaki M; Nushijima Y; Takiguchi S; Fujiwara Y; Nishida T; Mano M; Mori M; Doki Y
    Cancer; 2009 Jul; 115(14):3324-34. PubMed ID: 19452547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
    Akutsu Y; Hanari N; Yusup G; Komatsu-Akimoto A; Ikeda N; Mori M; Yoneyama Y; Endo S; Miyazawa Y; Matsubara H
    Ann Surg Oncol; 2011 Oct; 18(10):2946-51. PubMed ID: 21437756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis.
    Vallböhmer D; Drebber U; Schneider PM; Baldus S; Bollschweiler E; Brabender J; Warnecke-Eberz U; Mönig S; Hölscher AH; Metzger R
    J Surg Oncol; 2009 Jun; 99(7):409-13. PubMed ID: 19347901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIF-1alpha mRNA is not associated with histopathological regression following neoadjuvant chemoradiation in esophageal cancer.
    Ling FC; Leimbach N; Baldus SE; Buechel S; Neiss S; Brabender J; Drebber U; Dienes HP; Mueller RP; Hoelscher AH; Schneider PM
    Anticancer Res; 2006; 26(6B):4505-9. PubMed ID: 17201171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
    Duong C; Greenawalt DM; Kowalczyk A; Ciavarella ML; Raskutti G; Murray WK; Phillips WA; Thomas RJ
    Ann Surg Oncol; 2007 Dec; 14(12):3602-9. PubMed ID: 17896157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
    Mariette C; Taillier G; Van Seuningen I; Triboulet JP
    Ann Thorac Surg; 2004 Oct; 78(4):1177-83. PubMed ID: 15464466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
    Uchida K; Schneider S; Yochim JM; Kuramochi H; Hayashi K; Takasaki K; Yang D; Danenberg KD; Danenberg PV
    Clin Cancer Res; 2005 May; 11(9):3363-8. PubMed ID: 15867236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
    Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
    Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
    Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neoadjuvant treatment in surgery of esophageal cancer].
    Launois B; Raoul JL; Leprise E; Meunier B
    Bull Acad Natl Med; 2000; 184(8):1703-13; discussion 1714. PubMed ID: 11471389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neoadjuvant radiochemotherapy in the treatment of esophageal squamous carcinoma:Preliminary results in a series of 15 patients].
    Popescu I; Ionescu M; Ciurea S; Stănescu C; Gheorghe C; Anghel R; Croitoru A
    Chirurgia (Bucur); 2003; 98(6):499-508. PubMed ID: 15143606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?
    Piessen G; Briez N; Triboulet JP; Mariette C
    Ann Surg Oncol; 2007 Jul; 14(7):2036-44. PubMed ID: 17453293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
    Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
    Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
    Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.
    Miyazono F; Metzger R; Warnecke-Eberz U; Baldus SE; Brabender J; Bollschweiler E; Doerfler W; Mueller RP; Dienes HP; Aikou T; Hoelscher AH; Schneider PM
    Br J Cancer; 2004 Aug; 91(4):666-72. PubMed ID: 15213712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.